IPSEN : The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen's Prior Approval Supplement application Ipsen (Euronext: IPN; ADR: IPSEY) announced today ...

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...

Insulin-like growth factor I and growth hormone levels were adequately controlled on 4-weekly injections in nine patients. In these patients the effect of increasing the time interval between ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

The Food and Drug Administration has given Cipla its stamp of approval for lanreotide injection. The medication is the generic of Ipsen’s Somatuline Depot. It is indicated for the treatment of ...

PARIS -- Aug 31, 2007 - Regulatory News: Ipsen today announced that the U.S. Food and Drug Administration (FDA) has approved for marketing Somatuline(R) Depot (lanreotide) Injection 60, 90 and 120 mg ...

The redesigned syringe includes a needle shield removal system and more stable plunger and thermoform tray with recessed areas designed to help prevent accidental plunger depression. The Food and Drug ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) published today new data from seven abstracts to be presented at the hybrid-setting 19 th Annual European Neuroendocrine ...

MISSISSAUGA, ON, Jan. 7, 2020 /CNW/ - Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline ® Autogel ® (lanreotide injection) 60, 90, and 120 ...

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...

(RTTNews) - Ipsen said that new patient-reported data demonstrated high satisfaction levels and fewer patients reporting injection-site pain with Somatuline Autogel/Somatuline Depot or lanreotide. The ...